Could a diabetes drug shield heart transplant patients from kidney failure?

NCT ID NCT05321706

Ongoing Disease control Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial tests whether dapagliflozin (Farxiga), a drug originally developed for diabetes, can protect kidney function in people who have received a heart transplant. Kidney failure is a common and serious complication after heart transplant. The study involves 430 participants who will take either dapagliflozin or a placebo daily for one year, with researchers measuring changes in kidney function and other health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (Farxiga)
What this could lead to: If it works, this could offer a new way to protect kidney function in heart transplant patients, reducing the risk of kidney failure and improving long-term outcomes.
What could go wrong: This is a Phase 3 trial, but SGLT2 inhibitors have not been tested in heart transplant recipients before, so unexpected side effects or lack of benefit are possible. The trial lasts one year, so long-term effects are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART TRANSPLANT FAILURE KIDNEY FAILURE

Contacts and locations

Locations

Erasmus Medical Center

Rotterdam, Netherlands
Karolinska University Hospital

Stockholm, Sweden
Oslo University Hospital, Rikshospitalet

Oslo, Oslo, 0372, Norway
Skane University Hospital

Lund, 22185, Sweden
University Medical Center Groningen

Groningen, Netherlands
University Medical Center Utrecht

Utrecht, 3584, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.